GERMANTOWN, Md. & HILDEN, Germany–(BUSINESS WIRE)–QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test for use in diagnosing patients infected with the novel COVID-19 coronavirus.
{iframe}https://www.businesswire.com/news/home/20200331005294/en/QIAGEN-Receives-U.S.-FDA-EUA-QIAstat-Dx-test{/iframe}